Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this clinical trial is to learn if the use of MRI-guided irradiation increases the rates of rectal preservation
HYPOTHESIS
The implementation of Magnetic Resonance Image Guided Radiotherapy (MRgRT) into a TNT Program renders improved TME-free rates due to the better visualization and online dose-adaptation of the Gross Tumor Volume (GTV).
Rationale In the radiation setting, MRI provides superior soft tissue contrast compared to standard onboard X-ray imaging improving inter- and intra- observer delineation variation. MRgRT offers the opportunity to adapt the plan at each fraction to the anatomical changes seen. This is especially important in rectal cancer where the rectum is subject to interfractional position changes, volume shrinkage and intrafractional shape and size variation due to the variability in rectal filling.
Primary Objectives
A. To achieve 3-year TME-free survival of 75% while keeping 3-year DFS rates of 75%.
B. To achieve a CTCAE v5 grade 2-3 proctitis of less than 10% and grade 2-3 rectal bleeding rate of <2% at 2 years.
C. To achieve a Wexner Continence score of at least 90% over baseline at 2 years.
Secondary Objectives
A. Determination of blood and urine biomarkers of treatment response and toxicity .
B. Determination of radiomics biomarkers of treatment response and toxicity . C. Determination of rectal functionality with the Wexner Continence Score.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Dose Escalation Phase | Experimental | Dose Escalation MR-guided TNT |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MR-Guided Irradiation | Radiation | MR-Guided Irradiation |
|
| Measure | Description | Time Frame |
|---|---|---|
| Total Mesorectal Excision (TME)-free survival | To achieve 3-year TME-free survival of 75% while keeping 3-year DFS rates of 75%. | 5-years |
| Measure | Description | Time Frame |
|---|---|---|
| Proctitis/Rectal Bleeding | To achieve a CTCAE v5 grade 2-3 proctitis of less than 10% and grade 2-3 rectal bleeding rate of <2% at 2 years. | 5-years |
| Fecal Continence | To achieve a Wexner Continence score of at least 90% over baseline at 2 years. |
Not provided
Inclusion Criteria:
Patients aged 18 or older with primary Stage II (T3-4, N0) or Stage III (any T, N1-2) biopsy-proven rectal cancer
No prior radiation therapy to the target areas;
ECOG 0-2 with medical status not contraindicating treatment with radical intent including TNT and TME (if required) and with basal laboratory values as follows:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Beatriz Ramos Aguirre, M.S. | Contact | +34 948255400 | 2772 | ucicec@unav.es |
| Name | Affiliation | Role |
|---|---|---|
| Rafael MartÃnez-Monge, M.D. | ClÃnica Universidad de Navarra | Principal Investigator |
| Luis Fuertes, M.D. | ClÃnica Universidad de Navarra | Principal Investigator |
Not provided
On request
5-years
On request
Not provided
Not provided
| ID | Term |
|---|---|
| D012004 | Rectal Neoplasms |
| ID | Term |
|---|---|
| D015179 | Colorectal Neoplasms |
| D007414 | Intestinal Neoplasms |
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 5-years |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D004066 | Digestive System Diseases |
| D005767 | Gastrointestinal Diseases |
| D007410 | Intestinal Diseases |
| D012002 | Rectal Diseases |